AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUL 3 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - A vaccine directed against sperm antigen 17 showed potential as a successful treatment for ovarian cancer, researchers in Texas report.
The expression of sperm antigen 17 (Sp17) in normal tissue is limited. Therefore, it holds potential as a vaccine target for diseased tissues that do express the antigen.
M. Chirivainternati and colleagues at the Don and Sybil Harrington Cancer Center in Amarillo, Texas, prepared cytotoxic T-lymphocytes (CTL) specific to Sp17 after determining the gene expression of Sp17. A [superscript]51Cr release assay confirmed the identity of the CTLs.
The investigators found that Sp17 was expressed in the primary tumor cells of 70% of women with ovarian carcinoma. Using the peripheral blood of three cancer patients, Chirivainternati and associates were able to produce Sp17-specific CTLs restricted to human leukocyte antigen (HLA) class I.
The Sp17-specific CTLs could lyse Epstein-Barr virus-transformed lymphoblastoid cells and autologous cancer cells expressing Sp17. Antibodies against monomorphic class I-dependent molecules blocked lysis, but HLA class II could not (Tumor ...